Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can

---

Doval D., Cinieri S., Bozcuk H., Pierga J., Altundag K., Wang X., ...More

37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13 December 2014, vol.75, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Volume: 75
• City: San-Antonio
• Country: Northern Mariana Islands
• Akdeniz University Affiliated: Yes